Trial Profile
A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms POSEIDON
- Sponsors AstraZeneca; AstraZeneca AB
- 01 Feb 2024 This trail has been Completed in Bulgaria According to European Clinical Trials Database record.
- 01 Dec 2023 Results of patient-reported outcomes treated with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer, published in the Lung Cancer.
- 30 Sep 2023 Results assessing Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study published in the Clinical Pharmacology and Therapeutics